Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTQ1062 + Fulvestrant in Advanced HR+/HER2- Breast Cancer
NCT06172322Phase 1Recruiting
- Sponsor
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NTQ1062 in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative), sponsored by Nanjing Chia-Tai Tianqing Pharmaceutical. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 1 year and 1 more. Started Dec 2023; status: recruiting.
02
Drugs
NTQ1062
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT06172322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06172322.